Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 4, Single-Arm Study of Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab

Next Previous
Search
Trial Profile

Phase 4, Single-Arm Study of Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eculizumab (Primary) ; Ravulizumab (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use
  • Acronyms ALXN1210-PNH-401; Study 401
  • Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

  • 20 Jan 2023 Status changed from active, no longer recruiting to completed.
  • 13 Dec 2022 Interim Results(n=10, up to day 183 of follow-up) assessing the impact of switching treatment from fixed, high-dose IV eculizumab (1200 mg q2w) to weight-based IV ravulizumab q8w in patients with paroxysmal nocturnal hemoglobinuria presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 21 Sep 2021 Planned End Date changed from 1 Nov 2022 to 30 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top